H.C. Wainwright Thinks vTv Therapeutics’ Stock is Going to Recover

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on vTv Therapeutics (VTVTResearch Report) today and set a price target of $6.00. The company’s shares closed last Wednesday at $0.84, close to its 52-week low of $0.83.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.0% and a 35.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Citius Pharmaceuticals.

Currently, the analyst consensus on vTv Therapeutics is a Moderate Buy with an average price target of $6.00.

See Insiders’ Hot Stocks on TipRanks >>

vTv Therapeutics’ market cap is currently $75.54M and has a P/E ratio of -9.52.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Read More on VTVT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed